Stay updated on T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page history now includes a new revision entry for v3.3.2 and removes the older v3.2.0 from the visible list. These are administrative updates to the revision list and do not alter the study details or core content on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRemoval of a site-wide government funding/operating status notice from the Record History page; all other content and functionality appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check33 days agoChange DetectedA new version on 2025-10-28 updates the recruitment status to Active, not recruiting and adds/updates sections including Contacts/Locations, Study Design, Conditions, Oversight, Study Status, Study Identification, and Recruitment Status.SummaryDifference1%

- Check40 days agoChange DetectedA new version entry (Version 21, 2025-01-09) was added to the Record History. It documents an update to the study status and oversight.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference11%

- Check69 days agoChange DetectedUpdated the site/page version from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.3%

Stay in the know with updates to T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.